Tag

Semaglutide

All articles tagged with #semaglutide

health1 day ago•4 min saved

GLP-1 Medications Show Promise in Alcohol Use Disorder, Awaiting Approval

A Danish Lancet trial found the GLP-1 drug semaglutide reduced alcohol consumption and heavy drinking days over 26 weeks, adding to a growing body of research that GLP-1s may curb cravings for various substances. However, these drugs are not approved for alcohol use disorder and are prescribed today for diabetes or obesity; ongoing studies in the U.S. and elsewhere are exploring effects on other addictions and whether benefits persist after stopping treatment. If future trials confirm efficacy and safety, GLP-1s could become a treatment option pending regulatory approval.

via Gizmodo|

#addiction #alcohol-use-disorder #clinical-trials

health7 days ago•4 min saved

Wegovy May Carry Higher Risk of Rare Eye Stroke, Study Finds

A FAERS-based analysis of over 30 million adverse-event reports suggests Wegovy has the strongest association with ischemic optic neuropathy among semaglutide drugs, with higher signals in men and at higher Wegovy doses. While cases are rare and causation isn’t proven, researchers call for urgent prospective studies as GLP-1 obesity drugs become more widely used.

via ScienceDaily|

#glp-1 #health #ischemic-optic-neuropathy

health-and-fitness15 days ago•3 min saved

Inconsistent GLP-1 use may blunt weight-loss benefits, Penn study suggests

A Penn study in mice indicates that cycling GLP-1 weight-loss drugs like semaglutide on and off could trigger weight and fat gain and reduce drug effectiveness, highlighting consistency as a key takeaway, though it’s not yet proven in humans and more research is needed on other GLP-1 meds like Zepbound.

via 6abc Philadelphia|

#consistency #glp-1 #health-and-fitness

health28 days ago•6 min saved

Weight-Loss Drugs Show Long-Term Heart Benefits Across High-Risk Patients

A meta-analysis of 11 cardiovascular outcome trials (over 90,000 patients) finds GLP-1 receptor agonists reduce major cardiovascular events and all-cause mortality by about 13% over an average follow-up of nearly three years, with benefits seen in high-risk groups including those with or without diabetes. While GI side effects (nausea, vomiting) are more common, no significant safety signals like pancreatitis or hypoglycemia emerged. The results suggest these obesity/diabetes drugs may play a broader role in cardiovascular risk reduction and could influence clinical practice and policy.

via SciTechDaily|

#cardiovascular-disease #diabetes #glp-1-receptor-agonists

health1 month ago•54 min saved

Eye-stroke signals surface with Wegovy, but the risk remains very low and unproven

A British Journal of Ophthalmology study analyzed FDA adverse-event reports and found ischemic optic neuropathy (ION) in fewer than 1% of Wegovy users (28 of 3,070 reports) versus 47 of 20,608 for Ozempic, suggesting a possible Wegovy-specific signal but not proving causation. The data come from voluntary reports and don’t establish true risk; experts say the overall risk is very low and Wegovy’s benefits for weight management likely outweigh this potential issue. Regulators advise urgent medical care if eyesight worsens quickly, and Rybelsus showed no notable link in the study; dose differences remain unproven as a factor.

via Live Science|

#eye-stroke #health #ischemic-optic-neuropathy

health1 month ago•2 min saved

GLP-1 Drugs May Signal Higher Cognitive-Impairment Risk, Possibly Due to Longer Lifespans

A Johns Hopkins-led retrospective analysis of TriNetX data from ~65,000 older adults with type 2 diabetes found higher rates of cognitive impairment among GLP-1 agonist users (2.6%) versus non-users (1.3%). The authors caution the finding may reflect a survival effect—GLP-1 users live longer and thus have more time to develop cognitive issues—and that causality cannot be inferred from retrospective data; more research is needed to clarify any true risk.

via Futurism|

#cognitive-impairment #dementia #glp-1

health-and-medicine1 month ago•6 min saved

Endoscopic gut reset shows promise to preserve weight loss after GLP-1 therapy

A blinded, sham-controlled trial presented at DDW 2026 suggests that duodenal mucosal resurfacing, a minimally invasive endoscopic procedure, may help people retain most of their GLP-1–driven weight loss after stopping Ozempic/semaglutide. In the early REMAIN-1 data (45 participants: 29 treated, 16 sham), those who received resurfacing regained significantly less weight than controls six months after discontinuing the drug, with some patients regaining as little as ~7 pounds and keeping over 80% of their weight loss; no serious complications were reported and recovery is quick. The regimen is investigational, with larger topline results from REMAIN-1 anticipated later in 2026.

via Science Daily|

#duodenal-mucosal-resurfacing #health-and-medicine #minimally-invasive-procedure

health1 month ago•6 min saved

Reddit AI Scan Flags Potentially Hidden Side Effects in GLP-1 Weight-Loss Drugs

AI analyzed over 400,000 Reddit posts from about 70,000 users over five years to surface patient-reported side effects of GLP-1 medications (including semaglutide and tirzepatide). While many reported issues align with known effects, the study highlights potentially underreported symptoms such as menstrual irregularities and temperature-related changes, suggesting online patient discussions can provide early safety signals. Causation isn’t established, and researchers advocate broader, multilingual follow-up beyond Reddit to validate findings and inform clinicians.

via SciTechDaily|

#drug-safety #glp-1-drugs #health

health1 month ago•0 min saved

Tirzepatide may deliver bigger weight loss but greater lean-mass loss vs semaglutide, study suggests

A new study suggests Lilly’s tirzepatide yields more weight loss than Novo Nordisk’s semaglutide, but may also cause greater loss of lean body mass, indicating a potential trade-off in body composition.

via Endpoints News|

#glp-1 #health #lean-body-mass

health1 month ago•176 min saved

GLP-1 Drugs Show Health Benefits Beyond Weight Loss, From Liver to Heart

New findings indicate GLP-1 drugs like Wegovy and Zepbound can improve liver health and reduce inflammation even without weight loss, with trials showing cardiovascular and liver benefits beyond weight reduction; this could push insurers to rethink coverage criteria, though much of the mechanistic support comes from animal studies and human relevance remains under study.

via CNN|

#glp-1 #health #liver-health

health1 month ago•12 min saved

GLP-1 Weight-Loss Drugs May Quietly Reshape Libido

GLP-1 medications such as semaglutide and tirzepatide, used for obesity and type 2 diabetes, may impact sexual function by altering brain reward pathways and serotonin signaling, potentially affecting desire, arousal, and pelvic-floor function. While some users report reduced appetite and increased energy or confidence that can improve sex life, others experience lowered libido. Research is still limited, but experts suggest effects vary by individual and may be temporary; adjustments to dosage, lifestyle, and open conversations with a clinician can help manage changes and support sexual well-being.

via SELF Magazine|

#glp-1 #health #libido

health1 month ago•3 min saved

GLP-1 Weight Drugs: Debunking the 'bones-shredding' myth

A viral claim that GLP-1 drugs like semaglutide (Ozempic) shred bones isn’t supported. A preliminary AAOS presentation linked GLP-1 use with higher rates of osteoporosis and osteomalacia, but the absolute numbers were small (about 4% and 2%), and weight loss itself may drive risk. Doctors advise monitoring bone health and preventive steps (calcium, vitamin D, strength training). Another study at the same conference suggested GLP-1s could reduce some postoperative complications in orthopedic patients. GLP-1s have GI side effects and potential eye risks, but their overall benefits for obesity and diabetes remain substantial; the key is weighing benefits against risks with a clinician and avoiding sensational myths.

via Gizmodo|

#bone-health #glp-1s #health

health2 months ago•2 min saved

Stopping GLP-1 Drugs Sparks Quick Loss of Heart-Protection Benefits

A BMJ Medicine analysis of about 333,000 adults with diabetes found that consistent GLP-1 use lowers cardiovascular risk by 18% over three years, but stopping for as little as six months can raise risk by up to 8%, and pausing for one to two years can increase risk by roughly 22%, erasing the drug’s protection. Weight regain and a rebound in inflammation, blood pressure, and cholesterol accompany interruptions, which can leave a lasting “metabolic whiplash.” With many patients stopping or pausing due to cost, side effects, or shortages, the findings underscore the importance of maintaining GLP-1 therapy where possible.

via Futurism|

#cardiovascular-risk #diabetes #glp-1

health2 months ago•3 min saved

FDA Clears Higher-Dose Wegovy to Boost Weight Loss

The FDA approved Wegovy HD, a 7.2 mg weekly dose of semaglutide, a higher-dose version expected to boost weight loss. In trials, the higher dose yielded about 19% body-weight loss (roughly 47 lb) vs 16% (about 39 lb) with the 2.4 mg dose over about 17 months; the drug will be available in April with price to be announced. European regulators had approved it earlier. Side effects were common (GI issues in 70%+; 23% reported skin sensations) and serious adverse events occurred in ~7% of the higher-dose group. The jump from 2.4 mg to 7.2 mg is substantial, and real-world safety will need monitoring. An oral Wegovy pill was approved by the FDA in December for context.

via ScienceAlert|

#fda #health #obesity-drug

health2 months ago•2 min saved

FDA approves Wegovy HD, a higher-dose weight-loss option under a national priority program

The FDA cleared Wegovy HD (7.2 mg) for weight loss and long-term maintenance in adults with obesity or overweight plus a weight-related condition, marking the fourth approval under the Commissioner’s National Priority Voucher program. The higher dose yielded greater average weight loss with a safety profile consistent with prior semaglutide doses, though GI side effects were common and there is a boxed warning for thyroid C-cell tumors; the approval was granted to Novo Nordisk, and a June public hearing on the voucher program is planned.

via fda.gov|

#fda #health #national-priority-voucher